TBIO · Telesis Bio Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.57M | $1.55M | $3.44M | - | $5.56M | $8.65M | $6.32M | - | $6.67M | $5.66M |
| Cost of Revenue | $557.0K | $2.35M | $1.99M | - | $2.57M | $2.96M | $2.81M | - | $3.02M | $2.94M |
| Gross Profit | $1.01M | ($799.0K) | $1.45M | - | $3.00M | $5.69M | $3.51M | - | $3.66M | $2.71M |
| R&D | $2.17M | $2.47M | $2.92M | - | $4.12M | $4.59M | $5.12M | - | $5.82M | $7.12M |
| SG&A | $3.10M | $5.51M | $5.37M | - | $6.26M | $5.71M | $5.55M | - | $5.26M | $5.56M |
| Total Operating Expenses | $6.49M | $10.69M | $9.97M | - | $13.12M | $13.66M | $14.48M | - | $14.91M | $17.20M |
| D&A | $400.0K | $400.0K | $500.0K | - | $900.0K | $400.0K | $386.0K | - | $300.0K | $200.0K |
| Operating Income | ($5.48M) | ($11.49M) | ($8.52M) | - | ($10.12M) | ($7.97M) | ($10.97M) | - | ($11.25M) | ($14.49M) |
| Interest Expense | $219.0K | $707.0K | $217.0K | - | - | - | - | - | - | - |
| Income Tax | $1.0K | $1.0K | $2.0K | - | $14.0K | $4.0K | $3.0K | - | $6.0K | $6.0K |
| Net Income | ($6.64M) | ($12.59M) | ($8.64M) | - | ($10.63M) | ($8.29M) | ($11.12M) | - | ($12.31M) | ($14.83M) |
| EPS - Basic | ($4.09) | ($7.62) | ($5.52) | - | ($6.66) | ($5.04) | ($6.66) | - | ($7.56) | ($9.00) |
| EPS - Diluted | ($4.09) | ($7.62) | ($5.52) | - | ($6.66) | ($5.04) | ($6.66) | - | ($7.56) | ($9.00) |
Balance Sheet
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.72M | $6.40M | $10.62M | $1.57M | $17.39M | $46.61M | $23.36M | $30.42M | $24.74M | $22.28M |
| Accounts Receivable | $1.26M | $1.33M | $3.00M | $5.99M | $5.36M | $8.24M | $5.83M | $5.85M | $5.66M | $4.88M |
| Inventory | $1.10M | $1.36M | $3.67M | $4.03M | $4.27M | $3.86M | $2.29M | $2.20M | $2.19M | $1.78M |
| Accounts Payable | $1.49M | $1.54M | $1.91M | $3.28M | $2.40M | $1.43M | $2.44M | $1.29M | $1.62M | $3.87M |
| Current Assets | $8.12M | $15.16M | $23.39M | $30.35M | $52.71M | $61.54M | $42.94M | $55.09M | $62.19M | $72.03M |
| Total Assets | $24.74M | $52.73M | $63.33M | $70.41M | $105.03M | $114.53M | $89.16M | $81.36M | $88.14M | $97.28M |
| Current Liabilities | $6.63M | $8.01M | $6.41M | $8.18M | $25.42M | $10.39M | $11.24M | $13.50M | $12.81M | $18.24M |
| Long-term Debt | $5.84M | $5.28M | $5.22M | $5.27M | $5.17M | $19.87M | $19.75M | $19.65M | $19.47M | $10.71M |
| Total Liabilities | $20.86M | $42.78M | $41.68M | $40.87M | $58.54M | $58.46M | $52.54M | $34.80M | $34.83M | $32.56M |
| Stockholders' Equity | ($27.22M) | ($20.54M) | ($8.24M) | $238.0K | $17.77M | $27.92M | $36.62M | $46.56M | $53.31M | $64.72M |
| Retained Earnings | ($189.33M) | ($182.69M) | ($170.10M) | ($161.47M) | ($143.78M) | ($133.15M) | ($124.86M) | ($113.74M) | ($105.61M) | ($93.30M) |
Cash Flow
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($3.24M) | - | - | - | ($11.17M) | - | - | - |
| Investing Cash Flow | - | - | $12.25M | - | - | - | $4.12M | - | - | - |
| Financing Cash Flow | - | - | ($27.0K) | - | - | - | ($18.0K) | - | - | - |
| CapEx | - | - | $502.0K | - | - | - | $470.0K | - | - | - |
| Free Cash Flow | - | - | ($3.74M) | - | - | - | ($11.64M) | - | - | - |
Ratios
| Metric | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 64.4% | -51.5% | 42.0% | - | 53.9% | 65.8% | 55.6% | - | 54.8% | 48.0% |
| Operating margin | -349.7% | -741.4% | -247.7% | - | -181.9% | -92.1% | -173.7% | - | -168.6% | -256.2% |
| EBITDA margin | -324.2% | -715.5% | -233.2% | - | -165.7% | -87.4% | -167.6% | - | -164.1% | -252.6% |
| Net margin | -424.1% | -811.9% | -251.1% | - | -191.1% | -95.8% | -176.0% | - | -184.5% | -262.3% |
| Free cash flow margin | - | - | -108.7% | - | - | - | -184.2% | - | - | - |
| FCF / Net income | - | - | 0.43 | - | - | - | 1.05 | - | - | - |
| R&D / Revenue | 138.8% | 159.4% | 85.0% | - | 74.0% | 53.0% | 81.1% | - | 87.1% | 126.0% |
| SG&A / Revenue | 197.9% | 355.3% | 156.0% | - | 112.4% | 66.0% | 87.9% | - | 78.8% | 98.3% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -26.9% | -23.9% | -13.6% | - | -10.1% | -7.2% | -12.5% | - | -14.0% | -15.2% |
| Return on equity | 24.4% | 61.3% | 104.9% | - | -59.8% | -29.7% | -30.4% | - | -23.1% | -22.9% |
| Return on invested capital | - | - | - | - | -34.9% | -13.2% | -15.4% | - | -12.2% | -15.2% |
| Liquidity | ||||||||||
| Current ratio | 1.23 | 1.89 | 3.65 | 3.71 | 2.07 | 5.93 | 3.82 | 4.08 | 4.86 | 3.95 |
| Quick ratio | 1.06 | 1.72 | 3.08 | 3.22 | 1.91 | 5.55 | 3.62 | 3.92 | 4.68 | 3.85 |
| Cash ratio | 0.56 | 0.80 | 1.66 | 0.19 | 0.68 | 4.49 | 2.08 | 2.25 | 1.93 | 1.22 |
| Leverage | ||||||||||
| Debt / Equity | -0.21 | -0.26 | -0.63 | 22.14 | 0.29 | 0.71 | 0.54 | 0.42 | 0.37 | 0.17 |
| Debt / Assets | 0.24 | 0.10 | 0.08 | 0.07 | 0.05 | 0.17 | 0.22 | 0.24 | 0.22 | 0.11 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -25.0x | -16.3x | -39.3x | - | - | - | - | - | - | - |
| Equity multiplier | -0.91 | -2.57 | -7.69 | 295.84 | 5.91 | 4.10 | 2.43 | 1.75 | 1.65 | 1.50 |
| Liabilities / Assets | 0.84 | 0.81 | 0.66 | 0.58 | 0.56 | 0.51 | 0.59 | 0.43 | 0.40 | 0.33 |
| Efficiency | ||||||||||
| Asset turnover | 0.06 | 0.03 | 0.05 | - | 0.05 | 0.08 | 0.07 | - | 0.08 | 0.06 |
| Inventory turnover | 0.51 | 1.73 | 0.54 | - | 0.60 | 0.77 | 1.22 | - | 1.37 | 1.66 |
| Days sales outstanding | 294d | 314d | 318d | - | 351d | 348d | 337d | - | 310d | 315d |
| Days inventory outstanding | 720d | 211d | 672d | - | 607d | 476d | 299d | - | 266d | 220d |
| Days payable outstanding | 978d | 239d | 349d | - | 341d | 176d | 317d | - | 196d | 480d |
| Cash conversion cycle | 36d | 286d | 641d | - | 618d | 647d | 318d | - | 380d | 56d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | 31.6x | 30.3x | - | - | - | - |
| P / S | 4.3x | 4.1x | 3.8x | - | 100.8x | 97.9x | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -71.9% | -82.1% | -45.5% | - | -16.6% | 53.0% | 12.1% | - | 308.3% | 249.7% |
| Revenue CAGR (3y) | -1.4% | -1.4% | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -66.3% | - | -58.8% | - | -18.1% | 109.9% | 26.4% | - | 308.4% | 172.0% |
| Operating income growth (YoY) | 45.9% | -44.3% | 22.3% | - | 10.0% | 45.0% | -75.1% | - | -19.2% | -91.3% |
| Net income growth (YoY) | 37.5% | -51.9% | 22.3% | - | 13.7% | 44.1% | 15.7% | - | -175.8% | -263.3% |
| EPS growth (YoY) | 38.6% | -51.2% | 17.1% | - | 11.9% | 44.0% | 98.5% | - | 97.8% | 99.2% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | 67.9% | - | - | - | -123.1% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | -99.5% | -66.7% | -56.9% | -53.1% | -48.7% | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-12-31.
Product / service
$36.21M totalProduct$9.69M · 26.8%
License$8.70M · 24.0%
Collaboration Revenue$8.69M · 24.0%
Service$6.29M · 17.4%
Royalties And Other Revenue$2.84M · 7.8%
Peer comparison
Same SIC group: Laboratory Analytical Instruments
Comparing Telesis Bio Inc. against the 5 most active filers in the same SIC group.